Advertisement
AGYTF vs ARSUF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGYTF is a Hold and ARSUF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGYTF’s FA Score shows that 1 FA rating(s) are green whileARSUF’s FA Score has 1 green FA rating(s).
- AGYTF’s FA Score: 1 green, 4 red.
- ARSUF’s FA Score: 1 green, 4 red.
Price Growth
AGYTF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while ARSUF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.
Industries' Descriptions
@Pharmaceuticals: Generic (+6.26% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| AGYTF | ARSUF | AGYTF / ARSUF | |
| Capitalization | 544M | 1.78B | 31% |
| EBITDA | N/A | 158M | - |
| Gain YTD | 63.462 | 0.000 | - |
| P/E Ratio | N/A | 17.97 | - |
| Revenue | N/A | 872M | - |
| Total Cash | N/A | 116M | - |
| Total Debt | N/A | 386M | - |
AGYTF | ARSUF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 57 | |
PRICE GROWTH RATING 1..100 | 43 | 72 | |
P/E GROWTH RATING 1..100 | 5 | 48 | |
SEASONALITY SCORE 1..100 | 50 | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARSUF's Valuation (25) in the null industry is somewhat better than the same rating for AGYTF (90). This means that ARSUF’s stock grew somewhat faster than AGYTF’s over the last 12 months.
ARSUF's Profit vs Risk Rating (100) in the null industry is in the same range as AGYTF (100). This means that ARSUF’s stock grew similarly to AGYTF’s over the last 12 months.
ARSUF's SMR Rating (57) in the null industry is somewhat better than the same rating for AGYTF (94). This means that ARSUF’s stock grew somewhat faster than AGYTF’s over the last 12 months.
AGYTF's Price Growth Rating (43) in the null industry is in the same range as ARSUF (72). This means that AGYTF’s stock grew similarly to ARSUF’s over the last 12 months.
AGYTF's P/E Growth Rating (5) in the null industry is somewhat better than the same rating for ARSUF (48). This means that AGYTF’s stock grew somewhat faster than ARSUF’s over the last 12 months.
| AGYTF | ARSUF | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | N/A | N/A |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 3 days ago 27% | 3 days ago 20% |
| TrendMonth ODDS (%) | 3 days ago 25% | 3 days ago 20% |
| Advances ODDS (%) | N/A | N/A |
| Declines ODDS (%) | N/A | N/A |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | N/A | N/A |
Advertisement
AGYTF and
Correlation & Price change
A.I.dvisor indicates that over the last year, AGYTF has been loosely correlated with YCBD. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AGYTF jumps, then YCBD could also see price increases.
| Ticker / NAME | Correlation To AGYTF | 1D Price Change % | ||
|---|---|---|---|---|
| AGYTF | 100% | N/A | ||
| YCBD - AGYTF | 39% Loosely correlated | -10.98% | ||
| SDZXF - AGYTF | 20% Poorly correlated | +2.12% | ||
| PRFX - AGYTF | 0% Poorly correlated | -4.93% | ||
| APNHF - AGYTF | 0% Poorly correlated | N/A | ||
| ARSUF - AGYTF | 0% Poorly correlated | N/A | ||
More | ||||
ARSUF and
Correlation & Price change
A.I.dvisor tells us that ARSUF and GENPF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARSUF and GENPF's prices will move in lockstep.
| Ticker / NAME | Correlation To ARSUF | 1D Price Change % | ||
|---|---|---|---|---|
| ARSUF | 100% | N/A | ||
| GENPF - ARSUF | 23% Poorly correlated | N/A | ||
| AVCNF - ARSUF | 11% Poorly correlated | -2.28% | ||
| ALID - ARSUF | 8% Poorly correlated | N/A | ||
| BOIRF - ARSUF | 1% Poorly correlated | N/A | ||
| BIOVF - ARSUF | 1% Poorly correlated | N/A | ||
More | ||||